Eventi SITeCS

Detection and treatment of dyslipidaemias

Cinisello Balsamo (MI), 29-30 November 2023

[continua a leggere]

Present and Future Approaches to the Control of Dyslipidaemias

Virtual Edition, from Dec 22, 2020
[continua a leggere]

ECM FAD

LDL e malattie cardiovascolari: dalle linee guida alla terapia

[continua a leggere]

Il controllo del colesterolo LDL: presente e futuro

[continua a leggere]

European Atherosclerosis J

CopertinaGIFF European Atherosclerosis Journal
The  international, peer-reviewed, fully open access, four-monthly official journal of SITeCS

Rivista GIFF

CopertinaGIFF Giornale Italiano di Farmacoeconomia e Farmacoutilizzazione
Focus su utilizzo, rischio-beneficio e costo-efficacia dei farmaci e sulle politiche sanitarie

Newsletter

Per essere informati sulle novità di SITeCS iscrivetevi alla nostra newsletter inserendo il vostro indirizzo di posta elettronica

Area Soci

Login
Nome utente
Password
Password dimenticata?
Non sei ancora socio?

Diateca

Bookmark and Share

International Workshop - The role of dyslipidaemias in determining cardiovascular risk: from lifestyle to pharmacological intervention
Naples (Italy), November 17-18, 2018

 

 

 

 

 

Programme

 

 

 

November 17, 2018


INTRODUCTION

Introduction and scope of the meeting • A.L. Catapano
EAS activities and initiatives • L. Tokgözoglu

 

 

WHAT TO DO BEFORE INITIATING PHARMACOLOGICAL THERAPY

Lifestyle interventions • B. Föger
Role of nutraceuticals • M. Pirro


WHAT TO DO BEFORE INITIATING PHARMACOLOGICAL THERAPY

HDL • A.L Catapano
TG/NON-HDL-C • B. Ference
Addressing residual CV risk • A. Zambon


ACHIEVING LDL-C GOALS IN HIGH AND VERY HIGH RISK PATIENTS

Statins • E. Bruckert
Ezetimibe and Combination therapy • L. Masana
PCSK9 inhibitors • G. Watts


LIPID-LOWERING GUIDELINES: PRESENT AND FUTURE CHALLENGES

Round Table • A.L. Catapano and L. Tokgözoglu

 

 

 

November 18, 2018

 

FAMILIAL DYSLIPIDAEMIAS AND VERY HIGH RISK PATIENTS

FH detection and treatment • G. Watts
The very high risk patients • A. Zambon


INTERACTIVE SESSION: ANSWERS FROM THE PARTICIPANTS

Counseling and life style intervention: people at moderate risk • C. Jennings
Adherence and persistence to therapy: high CV risk patients • L. Masana

 

 

 


The programme was made possible thanks to an unrestricted educational grant from